The Translational Genomics Platform has become a new testing ground for diagnostics and follow-up, where patients and healthcare providers meet academic expertise and method development.
The aim is to contribute to the quality of life and lifespan of patients and to enable patient-specific treatment, with a focus on patients with cancer. The technology provides opportunities, for example, to assess the risk of relapse at an earlier stage than with conventional image analysis methods.
The Translational Genomics Platform is a partner in several ongoing national and international studies, especially at Sahlgrenska University Hospital, exploring the clinical utility of ultrasensitive nucleic acid analysis.
The Platform is part of Anders Ståhlberg Research group.